Highlights Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Real-time Estimate Cboe BZX Other stock markets 09:49:18 2024-05-22 am EDT			5-day change	1st Jan Change
6.49 ^USD	-1.82%		-4.85%	-28.03%

May. 15	Transcript : Travere Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM
May. 07	Canaccord Genuity Adjusts Price Target on Travere Therapeutics to $18 From $15, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Travere Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q1 Revenue $41.4M, vs. Street Est of $43.6M	May. 06	MT
EU Grants Conditional Marketing Approval for CSL Vifor, Travere’s Kidney Disease Treatment	Apr. 24	MT
Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization	Apr. 24	MT
CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® for the Treatment of IgA Nephropathy	Apr. 24	CI
Travere Therapeutics to Present Abstracts on Filspari® in Iga Nephropathy At World Congress of Nephrology and the American Nephrology Nurses Association	Apr. 03	CI
North American Morning Briefing : Stocks Set for -2-	Mar. 28	DJ
Travere Therapeutics Files Supplemental New Drug Application for Filspari to Treat IgA nephropathy	Mar. 11	MT
Travere Therapeutics, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration Seeking Full Approval of FILSPARI for Treatment of IgA Nephropathy	Mar. 11	CI
Travere Therapeutics Says EMA Committee Recommends Approval of Sparsentan to Treat Kidney Disease	Feb. 23	MT
Travere Therapeutics, Inc. and Csl Vifor Announce Sparsentan Receives Positive Chmp Opinion for the Treatment of Iga Nephropathy	Feb. 23	CI
Travere drug for rare kidney condition recommended for EU approval	Feb. 23	RE
Earnings Flash (TVTX) TRAVERE THERAPEUTICS Posts Q4 Revenue $45.1M, vs. Street Est of $41.8M	Feb. 15	MT
Travere Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Travere Therapeutics Signs Licensing Agreement With Renalys Pharma for Rare Kidney Disease Therapy	Jan. 26	MT
Travere Therapeutics, Inc. Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations	Jan. 25	CI
Travere Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023	Jan. 08	CI
Travere Therapeutics, Inc. Announces Program Updates and Anticipated 2024 Milestones	Jan. 08	CI
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria	Dec. 14	CI
Travere Therapeutics Says Pre-NDA Meeting With FDA for IgA Nephropathy Drug 'Successful'; Plans 20% Job Cut; Shares Jump Pre-Bell	Dec. 05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Travere Therapeutics, Inc.

Equities

TVTX

US89422G1076

Highlights

Filters